144 related articles for article (PubMed ID: 36595982)
41. [Bacillus Calmette Guerin as adjuvant treatment for superficial bladder tumors using two different therapeutic schemes].
Iturralde Codina A; Beyríe Tamayo W; Gozá León F; Muñoz YI
Arch Esp Urol; 2004; 57(6):606-18. PubMed ID: 15382436
[TBL] [Abstract][Full Text] [Related]
42. Immunoprotection against murine bladder carcinoma by octaarginine-modified liposomes incorporating cell wall of Mycobacterium bovis bacillus Calmette-Guérin.
Joraku A; Homhuan A; Kawai K; Yamamoto T; Miyazaki J; Kogure K; Yano I; Harashima H; Akaza H
BJU Int; 2009 Mar; 103(5):686-93. PubMed ID: 19040525
[TBL] [Abstract][Full Text] [Related]
43. Development of immunoadjuvants for immunotherapy of cancer.
Azuma I; Seya T
Int Immunopharmacol; 2001 Jul; 1(7):1249-59. PubMed ID: 11460306
[TBL] [Abstract][Full Text] [Related]
44. BCG Cell Wall Skeleton As a Vaccine Adjuvant Protects Both Infant and Old-Aged Mice from Influenza Virus Infection.
Kim KH; Lee YT; Park Y; Ko EJ; Jung YJ; Kim YJ; Jo EK; Kang SM
Biomedicines; 2021 May; 9(5):. PubMed ID: 34063125
[TBL] [Abstract][Full Text] [Related]
45. Comparative study on antitumor effect of cell-wall skeleton of Mycobacterium bovis BCG and Nocardia rubra, with reference to T-cell dependency and independency.
Yanagawa E; Yasumoto K; Ohta M; Nomoto K; Azuma I; Yamamura Y
Gan; 1979 Apr; 70(2):141-6. PubMed ID: 381087
[TBL] [Abstract][Full Text] [Related]
46. Effects of Mycobacterium bovis Calmette et Guérin (BCG) in oncotherapy: Bladder cancer and beyond.
Mukherjee N; Julián E; Torrelles JB; Svatek RS
Vaccine; 2021 Dec; 39(50):7332-7340. PubMed ID: 34627626
[TBL] [Abstract][Full Text] [Related]
47. Subcutaneous administration of a 10-fold-lower dose of a commercial human tuberculosis vaccine, Mycobacterium bovis bacillus Calmette-Guerin Danish, induced levels of protection against bovine tuberculosis and responses in the tuberculin intradermal test similar to those induced by a standard cattle dose.
Buddle BM; Hewinson RG; Vordermeier HM; Wedlock DN
Clin Vaccine Immunol; 2013 Oct; 20(10):1559-62. PubMed ID: 23925885
[TBL] [Abstract][Full Text] [Related]
48. WT1 peptide vaccination combined with BCG-CWS is more efficient for tumor eradication than WT1 peptide vaccination alone.
Nakajima H; Kawasaki K; Oka Y; Tsuboi A; Kawakami M; Ikegame K; Hoshida Y; Fujiki F; Nakano A; Masuda T; Wu F; Taniguchi Y; Yoshihara S; Elisseeva OA; Oji Y; Ogawa H; Azuma I; Kawase I; Aozasa K; Sugiyama H
Cancer Immunol Immunother; 2004 Jul; 53(7):617-24. PubMed ID: 15175906
[TBL] [Abstract][Full Text] [Related]
49. Osteomyelitis and septic arthritis after Mycobacterium Bovis BCG Therapy for Urinary Bladder Cancer.
Lee SC; Geannette CS
Clin Imaging; 2020 Dec; 68():179-183. PubMed ID: 32841934
[TBL] [Abstract][Full Text] [Related]
50. Bacillus Calmete-Guérin plus interferon-alpha2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity.
Lam JS; Benson MC; O'Donnell MA; Sawczuk A; Gavazzi A; Wechsler MH; Sawczuk IS
Urol Oncol; 2003; 21(5):354-60. PubMed ID: 14670544
[TBL] [Abstract][Full Text] [Related]
51. Bacillus Calmette-Guérin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature.
Pérez-Jacoiste Asín MA; Fernández-Ruiz M; López-Medrano F; Lumbreras C; Tejido Á; San Juan R; Arrebola-Pajares A; Lizasoain M; Prieto S; Aguado JM
Medicine (Baltimore); 2014 Oct; 93(17):236-254. PubMed ID: 25398060
[TBL] [Abstract][Full Text] [Related]
52. Simultaneous blocking of human Toll-like receptors 2 and 4 suppresses myeloid dendritic cell activation induced by Mycobacterium bovis bacillus Calmette-Guérin peptidoglycan.
Uehori J; Matsumoto M; Tsuji S; Akazawa T; Takeuchi O; Akira S; Kawata T; Azuma I; Toyoshima K; Seya T
Infect Immun; 2003 Aug; 71(8):4238-49. PubMed ID: 12874299
[TBL] [Abstract][Full Text] [Related]
53. Modulating the immune response to Bacillus Calmette-Guérin (BCG): a novel way to increase the immunotherapeutic effect of BCG for treatment of bladder cancer?
Sapre N; Corcoran NM
BJU Int; 2013 Oct; 112(6):852-3. PubMed ID: 24028766
[No Abstract] [Full Text] [Related]
54. Quadruple immunotherapy of Bacillus Calmette-Guérin, interferon, interleukin-2, and granulocyte-macrophage colony-stimulating factor as salvage therapy for non-muscle-invasive bladder cancer.
Steinberg RL; Nepple KG; Velaer KN; Thomas LJ; O'Donnell MA
Urol Oncol; 2017 Dec; 35(12):670.e7-670.e14. PubMed ID: 28801026
[TBL] [Abstract][Full Text] [Related]
55. Real-world treatment patterns and clinical outcomes of Japanese patients with non-muscle invasive bladder cancer receiving intravesical bacillus Calmette-Guérin treatment.
Miyake M; Kikuchi E; Shinozaki K; Piao Y; Hayashi N; Koto R; Jinushi M; Kobayashi T
Int J Urol; 2022 Oct; 29(10):1120-1129. PubMed ID: 35598101
[TBL] [Abstract][Full Text] [Related]
56. Bacillus Calmette-Guérin strain differences as the basis for immunotherapies against bladder cancer.
Miyazaki J; Onozawa M; Takaoka E; Yano I
Int J Urol; 2018 May; 25(5):405-413. PubMed ID: 29506322
[TBL] [Abstract][Full Text] [Related]
57. Prognostic significance of Bacillus Calmette-Guérin failure classification in non-muscle-invasive bladder cancer.
Shirakawa H; Kikuchi E; Tanaka N; Matsumoto K; Miyajima A; Nakamura S; Oya M
BJU Int; 2012 Sep; 110(6 Pt B):E216-21. PubMed ID: 22313616
[TBL] [Abstract][Full Text] [Related]
58. The efficacy of intravesical bacillus Calmette-Guerin in the treatment of patients with pT1 stage non-muscle-invasive bladder cancer.
Ajili F; Darouiche A; Chebil M; Boubaker S
Ultrastruct Pathol; 2013 Aug; 37(4):278-83. PubMed ID: 23789613
[TBL] [Abstract][Full Text] [Related]
59. Impact of maintenance therapy using a half dose of the bacillus Calmette-Guérin Tokyo strain on recurrence of intermediate and high-risk nonmuscle invasive bladder cancer: a retrospective single-center study.
Koguchi D; Matsumoto K; Hirayama T; Moroo S; Kobayashi M; Katsumata H; Ikeda M; Iwamura M
BMC Urol; 2020 Dec; 20(1):194. PubMed ID: 33298034
[TBL] [Abstract][Full Text] [Related]
60. Bacillus Calmette-Guerin strain may not effect recurrence-free survival when used intravesically with interferon-alpha2b for non-muscle-invasive bladder cancer.
Steinberg RL; Brooks NA; Thomas LJ; Mott SL; O'Donnell MA
Urol Oncol; 2017 May; 35(5):201-207. PubMed ID: 28041998
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
